Posts

Showing posts with the label Limb-Girdle Muscular Dystrophy Type 2

Limb-Girdle Muscular Dystrophy Type 2 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Limb-Girdle Muscular Dystrophy Type 2 (LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E, LGMD2F, LGMD2G, LGMD2I, LGMD2J, LGMD2L, Others (LGMD2H, LGMD2K, LGMD2M-Z)) includes forms of autosomal recessive characterized by progressive weakness of the muscles of the pelvic girdle, legs, arms, and shoulders. Progression of muscle weakness may be slow or rapid and may vary even among individuals in the same family. Intelligence is normal. The age of onset ranges from subgroup to subgroup. Overall, the beginning is more common in childhood, but it may occur in adulthood. Diagnosis of LGMD2A is complicated by phenotypic variability, lack of precise protein analysis, and absence of mutational hot spots in the CAPN3 gene. Children between the ages of 8-15 may range from 2-to 40 years of age. Most cases are characterized by muscle .weakness affecting the hip-girdle area, although the hip adductor muscles may be spared. ·        The prevalence of Limb-girdle muscular dyst...

Limb-Girdle Muscular Dystrophy Type 2 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Limb-Girdle Muscular Dystrophy Type 2 is a common chronic multifactorial ocular surface condition characterised by a failure to produce high-quality or sufficient amounts of tears to moisturise the eyes. Ageing, female sex, low humidity environments, systemic medications, and autoimmune disorders are all common risk factors for this syndrome. DED is classified as "dry eye with reduced tear production (aqueous deficient)" or "dry eye with increased evaporation of the tear film (hyper-evaporative type). Although 10% of people have aqueous deficient DED, more than 80% have hyper-evaporative type related to meibomian gland dysfunction (MGD) or a combination of the two. DED can significantly impact vision and quality of life because symptoms frequently interfere with daily activities such as writing, reading, or working on video display monitors. In the USA, the prevalence of Limb-Girdle Muscular Dystrophy Type 2 ranges from 5% to 7% in the adult population. The...

Limb-Girdle Muscular Dystrophy Type 2 – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Image
  Limb-Girdle Muscular Dystrophy Type 2 (LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E, LGMD2F, LGMD2G, LGMD2I, LGMD2J, LGMD2L, Others (LGMD2H, LGMD2K, LGMD2M-Z)) includes forms of autosomal recessive characterized by progressive weakness of the muscles of the pelvic girdle, legs, arms, and shoulders. Progression of muscle weakness may be slow or rapid and may vary even among individuals in the same family. Intelligence is normal. The age of onset ranges from subgroup to subgroup. Overall, the beginning is more common in childhood, but it may occur in adulthood. Diagnosis of LGMD2A is complicated by phenotypic variability, lack of precise protein analysis, and absence of mutational hot spots in the CAPN3 gene. Children between the ages of 8-and 15 may range from 2-to 40 years of age. Most cases are characterized by muscle .weakness affecting the hip-girdle area, although the hip adductor muscles may be spared. The prevalence of Limb-girdle muscular dystrophy type 2 varies from 47 to 53 ...